Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cancer Res. 2013 May 1;73(13):3913–3926. doi: 10.1158/0008-5472.CAN-12-4318

Figure 6.

Figure 6

T-cells mediate the antiglioma immune therapeutic efficacy of miR-124. (A) Histogram shows miR-124 transfection inhibited p-STAT3 activity in adoptively transferred T cells. (B) The treatment schema and volumes of subcutaneous GL261 tumors in C57BL/6J mice treated intratumorally with miR-124 or scramble control subcutaneously on day 7 (n=8/group/experiment) in the setting of in vivo CD4+ T-cells or CD8+ T-cell depletion. Arrows indicate days of treatment and tumor size measurements. *denotes a P value of <0.01 comparing the anti-CD4 or anti-CD8 depletion group with the isotype and miR-124-treated group. Standard deviations are shown. (C) The treatment schema and volumes of subcutaneous GL261 tumors in C57BL/6J mice treated intravenously with miR-124 or scramble control transfected CD3+ T-cells on day 14 (n=10/group/experiment). *denotes a P value of <0.01 comparing the miR-124 transfected T-cell treated group with the scramble control and untreated group.